Supplementary Equations

December 2, 2021

2-compartment PK model for bamlanivimab and etesevimab

$$\frac{dAb_{1c}}{dt} = -Ab_{1c} \cdot \frac{CL_{Ab1c}}{V_{Ab1c}} - Q_a \cdot \frac{Ab_{1c}}{V_{Ab1c}} + Qa \cdot \frac{Ab_{1p}}{V_{Ab1p}}$$
$$\frac{dAb_{1p}}{dt} = Q_a \cdot \frac{Ab_{1c}}{V_{Ab1c}} - Q_a \cdot \frac{Ab_{1p}}{V_{Ab1p}}$$
$$\frac{dAb_{2c}}{dt} = -Ab_{2c} \cdot \frac{CL_{Ab2c}}{V_{Ab2c}} - Q_b \cdot \frac{Ab_{2c}}{V_{Ab2c}} + Q_b \cdot \frac{Ab_{2p}}{V_{Ab2p}}$$
$$\frac{dAb_{2p}}{dt} = Q_b \cdot \frac{Ab_{2c}}{V_{Ab2c}} - Q_b \cdot \frac{V_{Ab2p}}{Ab_{2p}}$$

Equations describing phenomenological logarithmic activation of innate immune cells

1 Dendritic Cell Matuaration (*DC*)

$$\begin{aligned} \frac{dDC}{dt} &= \alpha_{DC} \left[k_V \cdot log(V) + k_I \cdot log(I) + k_D log(DAT1 + DAT2) \right] \left[k_{DC(TNF)} \cdot \left(\frac{(TNF\alpha)}{K_{DC(TNF)} + (TNF\alpha)} \right) + k_{DC(GM-CSF)} \cdot \left(\frac{(GM - CSF)}{K_{DC(IFN\gamma)} + (IFN\gamma)} \right) + k_{DC(GM-CSF)} \cdot \left(\frac{(GM - CSF)}{K_{DC(GM-CSF)} + (GM - CSF)} \right) \right] \\ & \left[\frac{K_{DC(IL10)}}{K_{DC(IL10)} + (IL10)} \right] - \beta_{DC} \cdot (DC) \end{aligned}$$

Mature (DC) are formed upon recognition of viral particles (V), infected cells (I), and damaged (AT1) and (AT2) cells. (DC) maturation is further induced by $(TNF\alpha)$, $(IFN\gamma)$, (GM - CSF), and inhibited by (IL10). Mature (DC) undergo nonspecific clearance at at a rate β_{DC} .

2 Macrophage Activation (*M*1)

$$\begin{aligned} \frac{dM1}{dt} &= \alpha_{M1} \bigg[k_V \cdot log(V) + k_I \cdot log(I) + k_D log(DAT1 + DAT2) \bigg] \bigg[k_{M1(TNF)} \cdot \bigg(\frac{(TNF\alpha)}{K_{M1(TNF)} + (TNF\alpha)} \bigg) + k_{M1(IFN\gamma)} \cdot \bigg(\frac{(IFN\gamma)}{K_{DC(IFN\gamma)} + (IFN\gamma)} \bigg) + k_{M1(GM-CSF)} \cdot \bigg) \bigg(\frac{(GM - CSF)}{K_{M1(GM-CSF)} + (GM - CSF)} \bigg) \bigg] \\ & \bigg[\frac{K_{M1(IL10)}}{K_{M1(IL10)} + (IL10)} \bigg] - \beta_{M1} \cdot (M1) \end{aligned}$$

Activated (M1) are formed upon recognition of viral particles (V), infected cells (I), and damaged (AT1) and (AT2) cells. (M1) activation is induced by $(TNF\alpha)$, $(IFN\gamma)$, (GM - CSF), and inhibited by (IL10). Activated (M1) undergo nonspecific clearance at at a rate β_{M1} .

3 Neutrophil Activation (N)

$$\begin{split} \frac{dN}{dt} &= \alpha_N \bigg[k_V \cdot log(V) + k_I \cdot log(I) + k_D log(DAT1 + DAT2) \bigg] \bigg[k_{M1(TNF)} \cdot \bigg(\frac{(TNF\alpha)}{K_{M1(TNF)} + (TNF\alpha)} \bigg) + k_{M1(IFN\gamma)} \cdot \bigg(\frac{(IFN\gamma)}{K_{DC(IFN\gamma)} + (IFN\gamma)} \bigg) + k_{M1(GM-CSF)} \cdot \bigg) \bigg(\frac{(GM - CSF)}{K_{M1(GM-CSF)} + (GM - CSF)} \bigg) \bigg] \\ & \quad ktr_N \cdot N_c \cdot \big(\frac{(IL17)}{km_{N_IL17} + (IL17)} \big) - \beta_N \cdot N - k_{tr(N)} \cdot N \end{split}$$

Activated (N) are formed upon recognition of viral particles (V), infected cells (I), and damaged (AT1) and (AT2) cells. (N) activation is induced by $(TNF\alpha)$, $(IFN\gamma)$, (GM - CSF), and inhibited by (IL10). Activated (N) undergo nonspecific clearance at at a rate β_N . Activated (N) migration is also induced by (IL17).